Garden debuts BLOOM platform to accelerate IP compliance in AI drug discovery

Garden has introduced BLOOM (Branching Lookup Optimized for Organic Molecules), a Markush structure search engine designed to give artificial intelligence (AI)-driven drug design teams near-instant verification of small-molecule intellectual property (IP) landscapes. This launch aims to allow researchers to iterate on potential drug candidates with legal certainty integrated directly into the design loop. The move responds to a rapidly growing challenge in pharmaceutical innovation—AI models are generating novel molecules faster than ever before, but the critical bottleneck has shifted to IP diligence. Knowing whether a compound is already protected before committing laboratory resources and budgets has become a decisive factor in time-to-market success. BLOOM addresses that bottleneck by building real-time, IP-aware checks into the early stages of drug discovery.

The system employs a graph-based, agentic traversal approach to compare Markush queries against millions of SMILES (Simplified Molecular Input Line Entry System) strings. This allows BLOOM to short-circuit invalid candidates at the level of local atom and bond features, significantly reducing wasted time and resources. The engine then generates a color-coded map confirming atom- and bond-level compliance, turning what was once a painstaking manual verification process into a built-in, automated step within AI-powered workflows. By integrating this function into the ideation stage, Garden seeks to make IP diligence a proactive, rather than reactive, part of discovery.

How BLOOM’s performance benchmarks reshape AI chemistry workflows

In internal benchmark testing, BLOOM delivered an average 32.44× speed improvement compared to a standard core-extraction string search, clocking 0.047 milliseconds per comparison versus 1.491 milliseconds. More critically, BLOOM’s algorithms identified correct matches that conventional string-based methods overlooked, including the successful detection of a single-hit query across a multi-million-record corpus. For companies operating in competitive therapeutic areas, this means that go/no-go decisions on novel chemical entities can be made during ideation, not weeks later after exhaustive manual reviews. That acceleration could translate directly into shortened development timelines and more agile research pipelines.

Traditional verification approaches often generate false positives, particularly when faced with nuanced bond counts and positional variations. Such inaccuracies can force medicinal chemists into labor-intensive atom-by-atom inspections. BLOOM reduces these false positives through its graph-reasoning capabilities, making the verification process not only faster but also more precise. This accuracy is especially important when dealing with minor chemical modifications—such as R-group substitutions—that may determine whether a molecule is patentable.

Integration with Garden’s patent database strengthens market positioning

One of BLOOM’s differentiating features is its deep integration with Garden’s proprietary patent database. Every SMILES match is linked to corresponding patent documents, enabling researchers to immediately access legal, technical, and competitive context. Garden’s in-house AI agent can summarize, compare, and help prune these result sets, providing a curated view of relevant claims. This integration supports workflows from rapid novelty triage to comprehensive freedom-to-operate (FTO) analyses, without requiring researchers to leave their molecular design environment.

The combined package positions Garden not only as a tool provider but as a potential strategic partner in IP-driven pharmaceutical innovation. By embedding patent analytics directly into the design pipeline, Garden aligns itself with the rising demand for vertical integration between computational chemistry and legal review. Analysts note that such integration could lower downstream litigation risks and reduce the number of abandoned candidates due to unforeseen IP conflicts.

Industry context: AI-driven drug design meets IP complexity

AI drug discovery has evolved rapidly over the past five years, with platforms from companies like Insilico Medicine, BenevolentAI, and Recursion Pharmaceuticals producing candidate molecules at unprecedented speed. According to industry research, the AI drug discovery market is projected to surpass $9 billion by 2030, growing at a compound annual growth rate (CAGR) above 30%. However, IP conflicts have emerged as a key barrier to commercialization. The use of Markush claims in patents—designed to cover broad chemical spaces—means that many seemingly novel AI-generated molecules can still fall within existing protections.

BLOOM enters this environment as a specialized solution to a widely acknowledged problem. By focusing on Markush structure matching, rather than relying on traditional substructure or string-based searches, BLOOM targets the very language and logic of chemical patenting. This capability could make it a sought-after tool for both AI-first biotech startups and established pharmaceutical companies seeking to modernize their IP checks.

Expert sentiment: speed and certainty as competitive advantages

Industry observers suggest that BLOOM’s greatest value proposition lies in its ability to combine speed and certainty at the ideation stage. “AI can propose thousands of viable chemistries in minutes. BLOOM closes the loop by telling you what’s already fenced off instantly,” said Adi Sidapara, founder and CEO of Garden, in the company’s launch announcement. For medicinal chemistry teams working under pressure to deliver lead candidates, the ability to filter out infringing molecules early could be a game-changer.

Kavin Sivakumar, Ph.D., founding machine learning researcher at Garden, emphasized the tool’s ability to capture subtle variations that determine patentability. “Small changes around an R-group can define patentability. BLOOM’s graph reasoning captures those subtleties at speed, so IP checks no longer throttle design,” Sivakumar noted. Analysts interpret these statements as signaling Garden’s intent to position BLOOM as a “must-have” in high-throughput AI-driven discovery pipelines.

Potential market impact and adoption outlook

While Garden has not disclosed specific pricing or licensing models for BLOOM, the platform’s integration with Garden’s patent database suggests a subscription-based model targeting enterprise pharmaceutical R&D teams, contract research organizations (CROs), and IP law firms specializing in chemistry. Given the growing emphasis on IP protection in drug development, BLOOM could see rapid uptake among companies seeking to reduce costly downstream litigation or patent invalidation risks.

In the short term, adoption is likely to be strongest among AI-native biotech firms that already operate at the intersection of computational chemistry and IP strategy. Over time, traditional pharmaceutical companies—often slower to change entrenched workflows—may adopt BLOOM as part of broader digital transformation initiatives. If adoption follows the trajectory of other specialized computational tools, Garden could secure a meaningful share of the AI-assisted medicinal chemistry software market within three years.

Linking today’s launch to broader sectoral shifts

The launch of BLOOM reflects a broader trend in pharmaceutical innovation: the convergence of AI-driven discovery and IP analytics. Over the past decade, computational chemistry tools have moved from being adjunct resources to central components of early-stage research. At the same time, patent litigation in the pharmaceutical sector has intensified, with blockbuster drug revenues often hinging on the scope and enforceability of chemical patents. By embedding IP awareness directly into molecule generation workflows, Garden’s BLOOM aligns with this shift toward integrated, multidisciplinary research environments.

Market analysts have also pointed out that the ability to “design around” existing patents in real time could foster a more competitive innovation landscape. Rather than discovering late in the process that a promising lead is blocked by prior art, companies could adapt molecular structures on the fly, potentially accelerating the path to patentable, novel compounds.

Future considerations for BLOOM and Garden

Looking ahead, Garden’s success with BLOOM will likely depend on its ability to maintain database coverage, improve matching algorithms, and integrate with third-party AI drug discovery platforms. The ongoing expansion of chemical patent databases, especially in emerging markets, could challenge the comprehensiveness of any single provider’s coverage. Garden’s commitment to keeping BLOOM’s patent repository current will be a key factor in sustaining its competitive advantage.

There is also the potential for BLOOM to be extended beyond small-molecule design. As biologics and peptide therapeutics gain prominence, analogous IP-aware design tools for larger biomolecules could open new market segments. For now, BLOOM’s focus on small molecules addresses the largest and most IP-complex segment of pharmaceutical research.